Skip to content
Catumaxomab
Removab (catumaxomab) is an antibody pharmaceutical. Catumaxomab was first approved as Removab on 2009-04-20. It has been approved in Europe to treat ascites and neoplasms. The pharmaceutical is active against T-cell surface glycoprotein CD3 epsilon chain. In addition, it is known to target epithelial cell adhesion molecule.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FX: Other monoclonal antibodies and antibody drug conjugates in atc
— L01FX03: Catumaxomab
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Stomach neoplasmsD013274EFO_0003897C16—21——3
NeoplasmsD009369C80——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C56—4———4
Peritoneal neoplasmsD010534—3———3
AdenocarcinomaD000230—2———2
Urinary bladder neoplasmsD001749C6721———2
Ovarian epithelial carcinomaD000077216—2———2
Fallopian tube neoplasmsD005185—1———1
AscitesD001201HP_0001541R18—1———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCATUMAXOMAB
INNcatumaxomab
Description
Catumaxomab (rat/mouse hybrid 3funct)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID509077-98-9
RxCUI—
ChEMBL IDCHEMBL2108581
ChEBI ID—
PubChem CID—
DrugBankDB06607
UNII IDM2HPV837HO (ChemIDplus, GSRS)
Target
Agency Approved
CD3E
CD3E
Organism
Homo sapiens
Gene name
CD3E
Gene synonyms
T3E
NCBI Gene ID
916
Protein name
T-cell surface glycoprotein CD3 epsilon chain
Protein synonyms
CD3-epsilon, CD3e, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), T-cell antigen receptor complex, epsilon subunit of T3, T-cell surface antigen T3/Leu-4 epsilon chain
Uniprot ID
P07766
Mouse ortholog
Cd3e (12501)
T-cell surface glycoprotein CD3 epsilon chain (P22646)
Alternate
EPCAM
EPCAM
Organism
Homo sapiens
Gene name
EPCAM
Gene synonyms
GA733-2, M1S2, M4S1, MIC18, TACSTD1, TROP1
NCBI Gene ID
4072
Protein name
epithelial cell adhesion molecule
Protein synonyms
Adenocarcinoma-associated antigen, CD326, Cell surface glycoprotein Trop-1, EGP, EGP314, Epithelial cell surface antigen, Epithelial glycoprotein, Epithelial glycoprotein 314, hEGP314, human epithelial glycoprotein-2, KS 1/4 antigen, KSA, Major gastrointestinal tumor-associated protein GA733-2, membrane component, chromosome 4, surface marker (35kD glycoprotein), trophoblast cell surface antigen 1, Tumor-associated calcium signal transducer 1
Uniprot ID
Q9UCD0
Mouse ortholog
Epcam (17075)
epithelial cell adhesion molecule (Q99JW5)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 858 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3 adverse events reported
View more details